ReviewJournal of toxicology2026
Effects of Legacy PFAS and Novel Alternatives on Thyroid Function in Mother‒Child Populations: A Systematic Review.
Review in Journal of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of Legacy PFAS and Novel Alternatives on Thyroid Function in Mother‒Child Populations: A Systematic Review.Journal of toxicology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Per- and polyfluoroalkyl substances (PFAS) are extensively utilized in industrial and consumer applications, such as firefighting foams, textiles, electronics, industrial coatings, food packaging, and household consumer products, due to their excellent chemical stability. However, legacy long-chain PFAS are prohibited because of their endocrine-disrupting properties, bioaccumulative nature, and potential carcinogenicity, followed by the emergence of new alternatives, such as short-chain congeners and novel PFAS alternatives. PFAS are known to disrupt endocrine function, and the thyroid gland, a critical endocrine organ, is particularly vulnerable to their effects. Mother‒child populations are more likely to be affected by PFAS due to their specific physiological characteristics, metabolic differences, and developmental stages. This paper reviews the exposure levels of legacy PFAS and their alternatives in maternal and infant blood and breast milk, and the relationship between PFAS exposure and thyroid hormone (TH) levels. It also examines the similarities and differences in the mechanisms by which different PFAS affect thyroid function. Research has revealed that both legacy and PFAS alternatives have been detected in maternal blood, infant blood, and breast milk. While legacy PFAS exhibit higher exposure levels with notable regional variations, the concentrations of PFAS alternatives, although lower, remain a concern. PFAS exposure affects TH in mothers and infants, with legacy PFAS having a more significant effect. The mechanisms underlying thyroid disruption caused by different PFAS are largely similar. However, PFAS alternatives are characterized by high protein affinity, ability to disrupt fatty acid metabolism, and high hydrophilicity, and may also increase the risk of thyroid cancer (TC). This study provides critical evidence for evaluating the safety of PFAS alternatives and provides a scientific foundation for developing preventive and regulatory measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.